Empagliflozin

This page is an automatically generated summary of information from the Federal Court, Federal Court of Appeal, Health Canada and other websites. This information should NOT be relied upon as it is automatically generated and has not been confirmed for accuracy.

Automatically generated on August 31, 2023.

Return to the list of Patented Medicine Litigation page.





Empagliflozin

GLYXAMBI, JARDIANCE, SYNJARDY – BOEHRINGER INGELHEIM (CANADA) LTD LTEE (NOC Search)

Patents:

  • 2443937: SANDOZ
  • 2443945: SANDOZ
  • 2557801: SUN PHARMA, APOTEX, JAMP, SANDOZ
  • 2606650: SANDOZ, APOTEX, JAMP, SUN PHARMA
  • 2696558: JAMP, APOTEX, SUN PHARMA, SANDOZ
  • 2751833: APOTEX, JAMP, SUN PHARMA, SANDOZ
  • 2752435: APOTEX, SUN PHARMA, JAMP, SANDOZ
  • 2813661: SANDOZ, JAMP, APOTEX, SUN PHARMA

APOTEX

JAMP

SANDOZ

SUN PHARMA


Return to the Patented Medicine Litigation page.

Canadian Intellectual Property